Rapivab (peramivir) / Shionogi, BioCryst  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapivab (peramivir) / BioCryst
ACTRN12607000282482: To evaluate the effects on time to clinical stability associated with treatment with peramivir administered intravenously compared to oral oseltamivir in adults hospitalized with acute serious or potentially life-threatening influenza

Not yet recruiting
2
120
 
BioCryst Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc.
Influenza, Life threatening comorbidities suchs as COPD, congestive heart failure and diabetes.
 
 
ACTRN12607000284460: To evaluate the efficacy of peramivir administered intramuscularly compared to placebo in adult subjects with uncomplicated acute influenza.

Recruiting
2
300
 
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc.
Uncomplicated influenza.
 
 
AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
2
3000
RoW
Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir
University of Oxford
Influenza, Influenza, Human
01/27
01/27

Download Options